Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan-Reference-Cited by-同舟云学术

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan

Published:2017-02-21 Issue:2 Volume:12 Page:e0171596
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wu Pei-Ying,Cheng Chien-Yu,Liu Chun-Eng,Lee Yi-Chien,Yang Chia-Jui,Tsai Mao-Song,Cheng Shu-Hsing,Lin Shih-Ping,Lin De-Yu,Wang Ning-Chi,Lee Yi-Chieh,Sun Hsin-Yun,Tang Hung-Jen,Hung Chien-Ching

Funder

the Centers for Disease Control, Taiwan

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference47 articles.

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,2015

2. European Guidelines for treatment of HIV-infected adults in Europe,2015

3. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015,2015

4. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what's new,2015

5. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study;AF Luetkemeyer;Clinical infectious diseases: an official publication of the Infectious Diseases Society of America,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis;BMC Infectious Diseases;2022-11-09

2. HIV and the Intestine;Textbook of Pediatric Gastroenterology, Hepatology and Nutrition;2021-11-25

3. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;J MICROBIOL IMMUNOL;2021

4. Cytoplasmic DNA: sources, sensing, and role in aging and disease;Cell;2021-10

5. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;Journal of Microbiology, Immunology and Infection;2021-10